Johnson & Johnson Releases Positive Study Data for Oncology Drug
On June 3, Johnson & Johnson’s (JNJ) pharma subsidiary, Jannsen, released data from a Phase 2 study of erdafitinib for the treatment of patients with metastatic or unresectable urothelial carcinoma (or mUC). Johnson & Johnson presented the study results at the 2018 ASCO (American Society of Clinical Oncology) Annual Meeting, along with results for some of its other oncology drug trials, as shown in the diagram below. Jannsen’s erdafitinib, a once-daily oral pan-FGFR (fibroblast growth factor receptor) inhibitor, was designated a breakthrough therapy by the FDA in March.